PR Newswire·Nov 9, 2026, 8:31 AM ET

MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026

MetaVia Inc. announced that an abstract for its novel drug DA-1726 has been accepted for presentation at ObesityWeek 2026 in Washington, DC from November 14-17, 2026.
The presentation, titled "DA-1726 Demonstrates Comparable Weight Loss & Distinct Metabolic Profile Compared With Retatrutide," will be delivered by Il Hoon Jeong on Saturday, November 14, 2026, from 7:30-8:30 pm ET in Exhibit Hall BCD.
DA-1726 is a once-weekly, subcutaneous dual agonist of GLP-1R & GCGR receptors engineered with a 3:1 potency ratio to balance appetite suppression with increased energy expenditure.
Interim Phase 1 Part 3B data at Day 109 showed DA-1726 achieved a 13.5% placebo-adjusted reduction in body weight & a 68% placebo-adjusted reduction in liver fat, alongside reductions in visceral & subcutaneous adipose tissue.
MetaVia plans to initiate a 48-week, non-biopsy Phase 2 study of DA-1726 for Metabolic & Alcohol-Associated Liver Disease (MetALD) & Alcohol-Associated Liver Disease (ALD) in the second half of 2027.
The company is also advancing vanoglipel (DA-1241), a GPR119-targeting drug, in combination with resmetirom for Metabolic Dysfunction-Associated Steatohepatitis (MASH), with a Phase 2a proof-of-concept study targeted for the first half of 2027.
Forward-looking statements in the release indicate risks regarding clinical timelines, regulatory approvals, capital sufficiency, & potential interactions between product candidates.